TY - JOUR
T1 - Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines
AU - Kumar Rao, P.
AU - Barker, Christopher
AU - Coit, Daniel G.
AU - Joseph, Richard W.
AU - Materin, Miguel
AU - Rengan, Ramesh
AU - Sosman, Jeffrey
AU - Thompson, John A.
AU - Albertini, Mark R.
AU - Boland, Genevieve
AU - Carson, William E.
AU - Contreras, Carlo
AU - Daniels, Gregory A.
AU - DiMaio, Dominick
AU - Durham, Alison
AU - Fields, Ryan C.
AU - Fleming, Martin D.
AU - Galan, Anjela
AU - Gastman, Brian
AU - Grossman, Kenneth
AU - Guild, Valerie
AU - Johnson, Douglas
AU - Karakousis, Giorgos
AU - Lange, Julie R.
AU - Margolin, Kim
AU - Nath, Sameer
AU - Olszanski, Anthony J.
AU - Ott, Patrick A.
AU - Ross, Merrick I.
AU - Salama, April K.
AU - Skitzki, Joseph
AU - Swetter, Susan M.
AU - Wuthrick, Evan
AU - McMillian, Nicole R.
AU - Engh, Anita
N1 - Publisher Copyright:
© 2020 Harborside Press. All rights reserved.
PY - 2020
Y1 - 2020
N2 - The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.
AB - The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.
KW - Antineoplastic Combined Chemotherapy Protocols/pharmacology
KW - Biomarkers, Tumor/analysis
KW - Bone Marrow/pathology
KW - Disease-Free Survival
KW - Drug Resistance, Neoplasm/genetics
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Humans
KW - Immunophenotyping
KW - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
KW - Lymph Nodes/cytology
KW - Lymphocytes/pathology
KW - Medical Oncology/methods
KW - Mutation
KW - Neoplasm Recurrence, Local/epidemiology
KW - Neoplasm Staging
KW - Organizations, Nonprofit/standards
KW - Prognosis
KW - Remission Induction/methods
KW - Transplantation, Homologous/standards
KW - United States/epidemiology
UR - https://www.scopus.com/pages/publications/85082319200
U2 - 10.6004/jnccn.2020.0006
DO - 10.6004/jnccn.2020.0006
M3 - Article
C2 - 32023533
AN - SCOPUS:85082319200
SN - 1540-1405
VL - 18
SP - 121
EP - 131
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 2
ER -